Small neurotrophic-mimetic peptide from CNTF research; preclinical only.
Also known as: P021 · CNTF-derived peptide
Part of the Neuropeptides & signaling cluster
Overview
P21 (P021) is a synthetic peptide designed as a mimetic of an active region of ciliary neurotrophic factor (CNTF). It has been studied in animal models of neurogenesis and cognitive aging and is not authorized as a medicine by Health Canada.
Source & context
Biological / chemical source: Synthetic mimetic of a ciliary neurotrophic factor (CNTF) region
Primary research or clinical context: Preclinical research compound (not authorized by Health Canada)
Design concept
Researchers reduced the active region of CNTF to a short, chemically stabilized peptide intended to cross the blood–brain barrier. The core is an acetylated tetrapeptide bearing an adamantane modification, illustrating peptidomimetic design strategies.
Evidence status
Published findings on P21 come from preclinical rodent studies, including models of Alzheimer-type pathology and cognitive aging. There are no completed human clinical trials, and this page does not present it as a treatment.
FAQ about P21
What is P21?+
P21 (P021) is a synthetic peptide designed as a mimetic of an active region of ciliary neurotrophic factor (CNTF). It has been studied in animal models of neurogenesis and cognitive aging and is not authorized as a medicine by Health Canada.
Is P21 an approved medicine?+
P21 is discussed here as a research / educational topic. Preclinical research compound (not authorized by Health Canada). This is not medical advice.
What is the typical length of P21?+
P21 is commonly described as approximately 4 amino acids (Research peptide).